Combination of CDX2 H-score quantitative analysis with CD3 AI-guided analysis identifies patients with a good prognosis only in stage III colon cancer.
Fiche publication
Date publication
juillet 2022
Journal
European journal of cancer (Oxford, England : 1990)
Auteurs
Membres identifiés du Cancéropôle Est :
Pr BOUCHE Olivier, Dr BOUVIER Anne-Marie, Pr GHIRINGHELLI François, Dr JOOSTE Valérie, Pr LEPAGE Côme, Mme TRUNTZER Caroline, Dr DERANGERE Valentin, Pr BIBEAU Frédéric , Dr MOLIMARD Chloé
Tous les auteurs :
Derangère V, Lecuelle J, Lepage C, Aoulad-Ben Salem O, Allatessem BM, Ilie A, Bouché O, Phelip JM, Baconnier M, Pezet D, Sebbagh V, Terrebonne E, Bouard G, Jooste V, Bouvier AM, Molimard C, Monnien F, Gonzalez D, Le Malicot K, Rageot D, Truntzer C, Bibeau F, Ghiringhelli F,
Lien Pubmed
Résumé
Stratification of colon cancer (CC) of patients with stage II and III for risk of relapse is still needed especially to drive adjuvant therapy administration. Our study evaluates the prognostic performance of two known biomarkers, CDX2 and CD3, standalone or their combined information in stage II and III CC.
Mots clés
Biomarkers, CD3, CDX2, Colon cancer, Immuno histochemistry, Prognosis
Référence
Eur J Cancer. 2022 07 1;172:221-230